Scleroderma Research Foundation
Scleroderma Research Foundation reported $13.1 million in revenue and $10.3 million in expenses for calendar year 2025. Of every $100 it spent, $91.04 went to program services, $3.39 to management and general costs and $5.57 to fundraising. Its largest source of revenue was program service revenue such as fees, sales and contracts: 45.0% of the total. The highest compensation it reported for one person was $527,375 (Chief Medical Officer). 6 people received more than $100,000 in reportable compensation. Revenue rose 234% between 2020 and 2025. Source: Form 990, 2025.
Where $100 of spending went
Calendar year 2025 · Form 990, Part IX, line 25 · total expenses $10MFor context, the median across 169 covered medical research charities: $87.02 programs, $12.87 management, $0.11 fundraising (medians computed separately, so they may not sum to $100).
Where $100 of revenue came from
Calendar year 2025 · Form 990, Part VIII · total revenue $13M- Contributions & grants (non-government)$43.34 $5.7M
- Program service revenue$44.67 $5.9M
- Investment income$11.99 $1.6M
Other revenue was negative: −$91,808. The bar shows the positive sources only.
The 990 scorecard · same measures for every charity, no grades
| Measure | 2025 | Median |
|---|---|---|
| Program services Part IX 25(B) ÷ 25(A) | 91.0% | 83.9% |
| Management & general Part IX 25(C) ÷ 25(A) | 3.4% | 12.4% |
| Fundraising Part IX 25(D) ÷ 25(A) | 5.6% | 0.1% |
| Fundraising cost per $1 of contributions Part IX 25(D) ÷ Part VIII 1h | $0.10 | $0.01 |
| Contributions & grants share of revenue Part VIII 1h ÷ 12 | 43.6% | 72.7% |
| Government grants share of revenue Part VIII 1e ÷ 12 | 0.0% | 0.0% |
| Program service revenue share Part VIII 2g ÷ 12 | 45.0% | 5.8% |
| Highest reported compensation Part VII-A, columns D–F | $527,375 | $628,890 |
| Highest compensation as share of expenses Part VII-A ÷ Part IX 25(A) | 5.11% | 1.94% |
| People paid over $100,000 Part VII, line 2 | 6 | 18 |
| Net assets, in months of expenses Part X 33(B) ÷ monthly expenses | 19.6 | 13.3 |
| Independent voting board members Part VI 1a–1b | 12 of 12 | 93.8% |
A median is context, not a target: hospitals, universities, food banks and grantmakers spend in very different ways. What these measures can and can't tell you.
What the money paid for, in its own words
2025 · Form 990, Part III · the three largest programs by expenseCONQUEST is a global, perpetual, clinical trial platform developed by the SRF in coordination with partner biopharmaceutical companies to accelerate the clinical development of agents for scleroderma. CONQUEST is designed to rapidly advance promising treatments for scleroderma and to identify those agents that should progress from phase 2b to phase 3 clinical trials. CONQUEST will make an enduring contribution to the scleroderma community by creating an ecosystem designed to enable rapid and efficient development of novel drugs for scleroderma patients
The mission of the Scleroderma Research Foundation (SRF) is to find, fund, and facilitate the most promising, highest-quality research to cure scleroderma. We recruit the best and the brightest researchers to understand the causes, discover treatments, and ultimately eradicate this disease . At the SRF, research is at the center of all we do. Our Research Program is governed by the Board of Directors and supported by a volunteer Scientific Advisory Board comprised of some of the world's most highly regarded scientists who are leaders in their field of expertise. The Board of Directors and…
SRF Education & Awareness Program: Many patients hear the word scleroderma for the first time when they are diagnosed. We strive to raise awareness and provide educational resources because lack of awareness about scleroderma often causes delays in treatment or misdiagnosis. As an innovator in scleroderma research, the SRF is uniquely qualified to provide those living with this disease, the medical community, and the general public with the most up-to-date, trusted and relevant news and information about complications, treatments, and related research through our website, webinars, annual…
Highest reported compensation
2025 · Form 990, Part VII, Section A · roles as filed; names are in the filing, not here| Role | From this org | From related orgs | Other | Total |
|---|---|---|---|---|
| Chief Medical Officer Listed in Part VII, 40.00 hrs/week | $526,440 | $0 | $935 | $527,375 |
| Executive Dir. Officer, 40.00 hrs/week | $220,205 | $0 | $18,062 | $238,267 |
| VP Communications Listed in Part VII, 40.00 hrs/week | $179,263 | $0 | $15,879 | $195,142 |
| Dir. Communication Listed in Part VII, 40.00 hrs/week | $130,689 | $0 | $7,851 | $138,540 |
| Sr. Acct. Manager Listed in Part VII, 40.00 hrs/week | $118,965 | $0 | $10,521 | $129,486 |
| Dir. Philanthropy Listed in Part VII, 40.00 hrs/week | $112,854 | $0 | $7,656 | $120,510 |
6 people received more than $100,000 in reportable compensation from Scleroderma Research Foundation (Part VII, line 2). Compensation of current officers, directors and key employees totaled $838K (Part IX, line 5).
6 years of filings
Form 990, Parts I, VII, IX and X · each row is that year's own filing, linkedGovernance answers, as filed
2025 · the organization's own yes/no answers; explanations, if any, are in Schedule O of the filing · what each means- Voting board members, and how many are independent Part VI, lines 1a–1b12 · 12 independent
- Audited financial statements Part XII 2bYes
- Conflict-of-interest policy Part VI 12aYes
- Whistleblower policy Part VI 13Yes
- Document retention policy Part VI 14Yes
- Independent process for top executive pay Part VI 15aYes
- Board given the 990 before filing Part VI 11aYes
- Family or business ties among insiders Part VI 2Yes
- Aware of a significant diversion of assets Part VI 5No
- Excess benefit transaction with an insider Part IV 25aNo
- Loans to or from insiders outstanding Part IV 26No
- Lobbying, or a 501(h) election in effect Part IV 4No
- Over $15,000 of professional fundraising services Part IV 18No
- Over $10,000 of activity outside the U.S. Part IV 14bYes
- Employees Part I, line 510
- Volunteers Part I, line 6255
Largest outside contractors
2025 · Form 990, Part VII, Section B · businesses only| Dinesh Khanna CONQUEST consultant | $195,000 |
Individuals listed as contractors are left out. 11 contractors were paid more than $100,000 in all.
Private foundation grants it received
21 private foundations reported grants to Scleroderma Research Foundation totaling $535K on their tax year 2023 Form 990-PF returns. See which foundations, on WHOFUNDS.
Source: WHOFUNDS open grant graph, matched from Form 990-PF Part XV.
Correct a figure or respond
Every number above is copied from Scleroderma Research Foundation's own Form 990. If one doesn't match the filing, that's our error and we'll fix it. If you work for Scleroderma Research Foundation, you can publish a response that is linked from this page.
Share or embed this breakdown
Of every $100 Scleroderma Research Foundation spent in 2025, $91.04 went to programs. The full breakdown, from its IRS Form 990:
Embed on your site
Similar-sized charities in this cause
- Research to Prevent Blindness Endowment FundNew York, NY · revenue $13M · programs 93.2% · 2024
- Friedreich's Ataxia Research AllianceSpringfield, VA · revenue $13M · programs 94.4% · 2024
- Cvpath InstituteGaithersburg, MD · revenue $13M · programs 91.9% · 2024
- Coalition of Cancer Cooperative GroupsPhiladelphia, PA · revenue $13M · programs 74.3% · FY2025
- Novus HealthSaint Louis, MO · revenue $13M · programs 95.4% · 2025
All medical research charities · Largest charities in California
Questions people ask
How much of Scleroderma Research Foundation's spending goes to programs?
In calendar year 2025, Scleroderma Research Foundation reported that 91.0% of its $10.3 million in expenses went to program services, 3.4% to management and general and 5.6% to fundraising (Form 990, Part IX).
How much does Scleroderma Research Foundation pay its top executive?
The largest total compensation Scleroderma Research Foundation reported for one person in calendar year 2025 was $527,375, for the role of Chief Medical Officer (Form 990, Part VII, including compensation from related organizations and other compensation).
Where does Scleroderma Research Foundation get its money?
Of $13.1 million in revenue in calendar year 2025, 43.6% came from contributions and grants and 45.0% from program service revenue (Form 990, Part VIII).
Is Scleroderma Research Foundation a registered charity?
The IRS lists EIN 68-0087234 as a 501(c)(3) organization (publicly supported organization (170(b)(1)(a)(vi))), and its records show contributions as tax-deductible. Form 990 filings on record here cover tax years 2020, 2021, 2022, 2023, 2024, 2025. A filing shows what the organization reported; it doesn't by itself show whether a program works.
Sources
- 2025: Form 990 for calendar year 2025, object 202601699349301445 · read the filing · XML
- 2024: Form 990 for calendar year 2024, object 202542409349300879 · read the filing
- 2023: Form 990 for calendar year 2023, object 202402419349301810 · read the filing
- 2022: Form 990 for calendar year 2022, object 202342649349301624 · read the filing
- 2021: Form 990 for calendar year 2021, object 202241609349300964 · read the filing
- 2020: Form 990 for calendar year 2020, object 202111819349301766 · read the filing
All filings for EIN 68-0087234: ProPublica Nonprofit Explorer · IRS Tax Exempt Organization Search. Figures are as the organization reported them; we have not audited them.